Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>
June 7, 2022
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of
CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
Kanagawa, Japan, June 7, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech
company engaged in the research and development of novel therapies for cancers,
today announced that it has presented the interim results from the Phase 1 clinical trialof CTX-712, a selective pan-CDC-like kinase (“CLK”) inhibitor discovered byChordia, at the 2022 Annual Meeting of the American Society of Clinical Oncology(ASCO), which was held from June 3 to June 7.
A Phase 1 clinical trial of CTX-712 in solid tumors and hematological malignancies
demonstrated a clinically acceptable safety profile. As for antitumor efficacy, it wasobserved in multiple subjects, establishing an initial Proof of Concept (POC). Doselimiting toxicities (DLTs) observed included dehydration, decreased platelet count,and hypokalemia, and the maximum tolerated dose (MTD) for twice-weekly dosing
was determined to be 140 mg. Additionally, two partial responses (PRs) and twocomplete responses (CRs) were observed in patients with ovarian cancer and acute
myeloid leukemia, respectively. A dose-dependent increase in systemic exposure wasobserved in pharmacokinetics (PK) analysis, and a dose-dependent increase in exonskipping of RNAs set as pharmacodynamics (PD) markers confirmed mRNA splicing
modification by CTX-712. Further studies are currently underway to determine therecommended Phase 2 dosing.
“It is a great honor to be involved in the first-in-human clinical trial of a new
anticancer drug candidate with a novel mechanism of action,” said Dr. Noboru
Yamamoto, Director of the Department of Experimental Therapeutics at the National
Cancer Center Hospital and Principal Investigator of the study. “Although it is still inthe early stages of clinical trials, we hope that CTX-712 will become an effective
treatment for patients with advanced, relapsed, or refractory malignancies in the future.”
ASCO abstract number: 3080
Title: A First-in-Human Phase 1 Study of CTX-712 in Patients with Advanced,
Relapsed or Refractory Malignant Tumors
About CTX-712
CTX-712 is a first-in-class, orally available and selective small molecule inhibitor ofCDC-like kinase (CLK), a key regulator of the RNA splicing process that plays animportant role in cell growth. CTX-712 inhibits the growth of various human tumor
cell lines in vitro, and in addition, exhibits antitumor activity in multiple xenograft
mouse models in vivo.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

Details of Phase 1 Clinical Trial
The Phase 1 clinical trial in Japan is investigating the tolerability, safety, andpharmacokinetics (PK) of CTX-712 in patients with advanced, relapsed, or refractory
malignancies. For details of the study, please refer to JapicCTI-184188.
About RNA Splicing
The RNA immediately after transcription is called precursor messenger RNA whichcontains noncoding sequences (introns) as well as coding sequences (exons) that areneeded to make proteins. RNA splicing is a process to remove the introns and connect
the exons to form mature mRNA, which is then translated into protein.
About CDC-like Kinases (CLKs)
Kinase is a general term for enzymes that catalyze the transfer of phosphate groups inbiological substances, such as ATP, over to target substances that are called substrates.
Over 500 protein kinases are known in humans, of which the CLK family consists offour members – CLK1, CLK2, CLK3, and CLK4, and phosphorylates serine/argininerich (SR) proteins as substrates.
About Serine/Arginine-rich Proteins (SR Proteins)
SR protein is a general term for a group of proteins with serine (S) and arginine (R)rich SR domains, of which about 10 types have been reported in humans. The serinein the SR domain is phosphorylated by CLK kinase. The phosphorylated SR proteinsbind to the exon region of the precursor mRNA and facilitate the incorporation of thebound exon into the mature mRNA during splicing.
About Exon Skipping
When CTX-712 inhibits CLK kinases and the SR protein dephosphorylates, a splicing
change called exon skipping occurs, in which the exons fail to be incorporated into themature mRNA.
Important Notice
In this press release, the definition of “press release” covers any oral presentation,question and answer session, and written and/or oral materials discussed or distributedby Chordia Therapeutics in connection with this press release. This press release(including the oral description and related questions and answers) is not intended toconstitute, represent, or form part of any offer, invitation, or solicitation to purchase
and/or acquire anything, including securities.
Disclaimer
Any announcements by Chordia Therapeutics, including this press release, may
contain information on products derived from pharmaceutical developments, but areintended to inform the latest information related to Chordia’s business, and notintended as promotions, solicitations, advertisements, or to provide medical advice.
Forward-Looking Statements
This press release and materials distributed in connection with this press release may
contain forward-looking statements, information, beliefs, and opinions concerning ourChordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

future operations, future positioning, and performance, including estimates,projections, goals, and plans. Forward-looking statements may include, but are notlimited to, expressions such as "goals," "plans," "beliefs," "hopes," "continues,""expects," "intends," "assures," "will," "may," "should," "would," "could," "estimates,""projects," and/or other similar expressions, or the negative thereof. These forwardlooking statements are based on assumptions concerning a number of important factors,
including the following, which could cause actual results to differ materially fromthose expressed or implied by the forward-looking statements; highly influential
factors that include economic conditions surrounding our global business, which
include general economic conditions in Japan and the United States, competitive
pressures and developments including changes in applicable laws and regulations,which include global healthcare reform, uncertainty as to our clinical success, andchallenges inherent in new product development (which include regulatory decisions
and their timing,) uncertainty as to the commercial success of new and existingproducts manufacturing difficulties, delays fluctuations in interest rates and exchange
rates claims or concerns regarding the safety or efficacy of commercial products or
product candidates the impact of a health crisis, such as the COVID-19 pandemic, on
Chordia and its customers and suppliers (including foreign governments in countries
in which the Company conducts business) or other aspects of its business. We
undertake no obligation to update any forward-looking statements contained in thispress release or any other forward-looking statements we may make, except as requiredby law or stock exchange rules. Past performance is not indicative of future operating
results, and any of our operating results or statements in this press release are notestimates, forecasts, warranties, or projections of our future operating results.
About Chordia Therapeutics
Chordia was established in November 2017 at Shonan Health Innovation Park(“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged
in the research and development of novel therapies for cancers, with the goal ofresearching and developing first-in-class anti-cancer drugs and creating innovative
new drugs.
In addition to its leading program for CTX-712, Chordia is engaged in the research of
several developments in our pipeline, including CTX-439, a CDK12 inhibitor, whichis expected to be effective in cancers with specific abnormalities, as well as GCN2inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, contact Kentaro Kume, IR: info@chordiatherapeutics.com